Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
DNV Capital (德诺资本) is an international investment institution founded in 2011 and headquartered in Shenzhen, China. The firm focuses on new productivity, primarily within the healthcare and hard technology sectors. DNV Capital collaborates closely with industry experts and capital elites to provide a range of services, including equity investment, mergers and acquisitions, asset restructuring, and project financing. The firm has established itself as a significant player in the Asian investment landscape, particularly in healthcare and technology.
As of now, DNV Capital manages a portfolio of 10 companies and has participated in various funding rounds, including a notable CNY 300M Series D for Sinovation, a company specializing in neurosurgical robotics. The firm emphasizes innovation and aims to support the growth of high-quality enterprises through its extensive network and expertise. DNV Capital's commitment to the healthcare and hard technology sectors positions it as a key partner for startups in these fields.
DNV Capital primarily invests in high-quality enterprises at the growth, expansion, and maturity stages. The firm targets sectors such as healthcare and hard technology, with a specific focus on chemical drugs, medical devices, biopharmaceuticals, precision medicine, AI healthcare, traditional Chinese medicine, and consumer healthcare. In the hard technology domain, DNV Capital invests in artificial intelligence, aerospace, next-generation information technology, and new materials.
The firm seeks to partner with companies that demonstrate strong potential for innovation and growth. DNV Capital values collaboration with industry experts and aims to leverage its global resources to drive the success of its portfolio companies. The investment strategy is designed to support enterprises that are not only financially viable but also contribute to advancements in their respective fields.
DNV Capital's portfolio includes a diverse range of companies, primarily in the healthcare and hard technology sectors. Notable portfolio companies include:
This portfolio reflects DNV Capital's commitment to investing in companies that are at the forefront of technological and medical advancements.
林云峰 (Lin Yunfeng) - Managing Partner: Lin has extensive experience in venture capital and private equity, focusing on healthcare investments. He has led numerous successful funding rounds and has a strong background in strategic management.
王屏 (Wang Ping) - Partner: Wang specializes in hard technology investments, particularly in artificial intelligence and next-generation information technology. He has a proven track record in identifying high-potential startups.
杨哲 (Yang Zhe) - Partner: Yang brings expertise in biopharmaceuticals and medical devices, having previously worked with leading firms in the healthcare sector.
吕舟 (Lu Zhou) - Partner: Lu has a strong background in financial analysis and investment strategy, focusing on growth equity opportunities.
丁建泽 (Ding Jianzhe) - Investment Department: Ding is involved in sourcing and evaluating potential investment opportunities across various sectors.
贺忆涛 (He Yitao) - Investment Department: He supports the investment team in due diligence and market research.
张君雅 (Zhang Junya) - Finance Department: Zhang manages financial operations and reporting for the firm.
苗钟元 (Miao Zhongyuan) - Fund Management Department: Miao oversees fund performance and investor relations.
朱春艳 (Zhu Chunyan) - Fund Management Department: Zhu is responsible for fund administration and compliance.
To pitch to DNV Capital, founders should visit the firm's website at www.dnvcapital.com or send an email to DNVC@DNVC.com. The pitch deck should include a clear overview of the business model, market opportunity, competitive landscape, and financial projections. Founders are encouraged to provide detailed information about their team and any traction achieved to date.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
In 2023, DNV Capital participated in a CNY 300M Series D financing round for Sinovation, a company specializing in neurosurgical robotics. This investment highlights DNV Capital's commitment to advancing healthcare technology in China.
Additionally, DNV Capital has been actively expanding its portfolio, focusing on innovative healthcare solutions and advanced technologies. The firm continues to seek out high-quality enterprises that align with its investment thesis in the healthcare and hard technology sectors.
What are DNV Capital's investment criteria?
DNV Capital invests in high-quality enterprises primarily in the healthcare and hard technology sectors, focusing on growth, expansion, and maturity stages.
How can I apply or pitch to DNV Capital?
Founders can pitch their ideas through the firm's website at www.dnvcapital.com or via email at DNVC@DNVC.com.
What makes DNV Capital different from other investors?
DNV Capital distinguishes itself through its strong focus on healthcare and hard technology, leveraging a network of industry experts to support portfolio companies.
What is the geographic scope of DNV Capital's investments?
The firm primarily invests in Asia, with a strong emphasis on the Chinese market.
What is DNV Capital's post-investment involvement?
DNV Capital provides strategic guidance, access to industry expertise, and collaboration opportunities to its portfolio companies.
What is the typical check size for investments?
While specific check sizes are not disclosed, DNV Capital focuses on growth equity investments, which typically involve larger funding amounts.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.